{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:33:12Z","timestamp":1750221192557,"version":"3.41.0"},"publisher-location":"New York, NY, USA","reference-count":35,"publisher":"ACM","license":[{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.acm.org\/publications\/policies\/copyright_policy#Background"}],"content-domain":{"domain":["dl.acm.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,12]]},"DOI":"10.1145\/3299852.3299854","type":"proceedings-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T12:18:36Z","timestamp":1553516316000},"page":"37-41","update-policy":"https:\/\/doi.org\/10.1145\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Momentous Innovations in the Prospective Method of Drug Development"],"prefix":"10.1145","author":[{"given":"S. Jafar Ali","family":"Ibrahim","sequence":"first","affiliation":[{"name":"Anna University, Chennai, Tamilnadu, India"}]},{"given":"M.","family":"Thangamani","sequence":"additional","affiliation":[{"name":"Kongu Engineering College, Perundurai, Tamilnadu, India"}]}],"member":"320","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"key":"e_1_3_2_1_1_1","unstructured":"ASCO. Clinical trial design and methodology {Internet}. Alexandria (VA): American Society of Clinical Oncology. Available from: https:\/\/www.asco.org\/research-progress\/clinical-trials\/clinicaltrial-resources\/clinical-trial-design-and-methodology.  ASCO. Clinical trial design and methodology {Internet}. Alexandria (VA): American Society of Clinical Oncology. Available from: https:\/\/www.asco.org\/research-progress\/clinical-trials\/clinicaltrial-resources\/clinical-trial-design-and-methodology."},{"key":"e_1_3_2_1_2_1","volume-title":"draft guidance. Silver Spring (MD): US Food and Drug Administration","author":"Adaptive","year":"2010","unstructured":"FDA. Adaptive design clinical trials for drugs and biologics : draft guidance. Silver Spring (MD): US Food and Drug Administration , 2010 . Available from: https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM201790.pdf. FDA. Adaptive design clinical trials for drugs and biologics: draft guidance. Silver Spring (MD): US Food and Drug Administration, 2010. Available from: https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM201790.pdf."},{"key":"e_1_3_2_1_3_1","unstructured":"CFDA. {Biostatistics guidelines for drug clinical trials}.  CFDA. {Biostatistics guidelines for drug clinical trials}."},{"key":"e_1_3_2_1_4_1","unstructured":"FDA. FDA approves first cancer treatment for any solid tumor with a specific genetic feature {Internet}. Silver Spring (MD): US Food & Drug Administration. Available from:https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm560167.htm.  FDA. FDA approves first cancer treatment for any solid tumor with a specific genetic feature {Internet}. Silver Spring (MD): US Food & Drug Administration. Available from:https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm560167.htm."},{"key":"e_1_3_2_1_5_1","unstructured":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158\/ KEYNOTE-158) {Internet}. Bethesda (MD): ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02628067.  Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158\/ KEYNOTE-158) {Internet}. Bethesda (MD): ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02628067."},{"volume-title":"Merck & Co","author":"Investigational","key":"e_1_3_2_1_6_1","unstructured":"Investigational immunotherapy trials for solid tumors {Internet}. Kenilworth (NJ) : Merck & Co , Inc . Available from: https:\/\/keynoteclinicaltrials.com\/trials\/solid-tumors. Investigational immunotherapy trials for solid tumors {Internet}. Kenilworth (NJ): Merck & Co, Inc. Available from: https:\/\/keynoteclinicaltrials.com\/trials\/solid-tumors."},{"key":"e_1_3_2_1_7_1","unstructured":"Ray T. Basket study supported keytruda pan-cancer indication but challenges remain {Internet}. New York (NY): Genomewide. Available from: https:\/\/www.genomeweb.com\/cancer\/basket-studysupported-keytruda-pan- cancer-indication-challenges-remain.  Ray T. Basket study supported keytruda pan-cancer indication but challenges remain {Internet}. New York (NY): Genomewide. Available from: https:\/\/www.genomeweb.com\/cancer\/basket-studysupported-keytruda-pan- cancer-indication-challenges-remain."},{"key":"e_1_3_2_1_8_1","unstructured":"A study of vemurafenib in participants with BRAF V600 mutation-positive cancers {Internet}.Bethesda (MD): ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01524978.  A study of vemurafenib in participants with BRAF V600 mutation-positive cancers {Internet}.Bethesda (MD): ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01524978."},{"key":"e_1_3_2_1_9_1","doi-asserted-by":"crossref","unstructured":"Hyman M. Blay J. Y. Chau I. etal VE-BASKET a first-in-kind phase II histology-independent \"basket\" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m). Journal of Clinical Oncology 32 No 15_suppl (May 2014) 2533--2533. 2014;32 ((suppl.)):2533.  Hyman M. Blay J. Y. Chau I. et al. VE-BASKET a first-in-kind phase II histology-independent \"basket\" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m). Journal of Clinical Oncology 32 No 15_suppl (May 2014) 2533--2533. 2014;32 ((suppl.)):2533.","DOI":"10.1200\/jco.2014.32.15_suppl.2533"},{"key":"e_1_3_2_1_10_1","unstructured":"FDA announces first approval of targeted therapy based on basket study {Internet}. New York (NY): Memorial Sloan Kettering Cancer Center. Available from: https:\/\/www.mskcc.org\/trending-topics\/fda-announces-first-approval-targeted-therapy-based-basket-study.  FDA announces first approval of targeted therapy based on basket study {Internet}. New York (NY): Memorial Sloan Kettering Cancer Center. Available from: https:\/\/www.mskcc.org\/trending-topics\/fda-announces-first-approval-targeted-therapy-based-basket-study."},{"key":"e_1_3_2_1_11_1","volume-title":"Biostatistical review of new drug applications in Japan - current and future activity","author":"Ando Y.","year":"2015","unstructured":"Ando , Y. Biostatistical review of new drug applications in Japan - current and future activity . Tokyo : Pharmaceuticals and Medical Devices Agency , 2015 . Available from: https:\/\/www.pmda.go.jp\/ files\/000207303.pdf. Ando, Y. Biostatistical review of new drug applications in Japan - current and future activity. Tokyo: Pharmaceuticals and Medical Devices Agency, 2015. Available from: https:\/\/www.pmda.go.jp\/ files\/000207303.pdf."},{"key":"e_1_3_2_1_12_1","unstructured":"ADDPLAN\u00ae {Internet}. Dublin: ICON. Available from: http:\/\/www.iconplc.com\/innovation\/addplan\/.  ADDPLAN\u00ae {Internet}. Dublin: ICON. Available from: http:\/\/www.iconplc.com\/innovation\/addplan\/."},{"key":"e_1_3_2_1_13_1","doi-asserted-by":"crossref","unstructured":"Treweek S. Lockhart P. Pitkethly M. etal Methods to improve recruitment to randomized controlled trials: Cochrane systematic review and meta-analysis. BMJ Open. 2013;3:e002360.  Treweek S. Lockhart P. Pitkethly M. et al. Methods to improve recruitment to randomized controlled trials: Cochrane systematic review and meta-analysis. BMJ Open. 2013;3:e002360.","DOI":"10.1136\/bmjopen-2012-002360"},{"key":"e_1_3_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/2168479015580384"},{"key":"e_1_3_2_1_15_1","unstructured":"JPRN. Japan primary registries network {Internet}. Available from: http:\/\/rctportal.niph.go.jp\/.  JPRN. Japan primary registries network {Internet}. Available from: http:\/\/rctportal.niph.go.jp\/."},{"key":"e_1_3_2_1_16_1","unstructured":"PCORI. About our research {Internet}. Washington (DC): Patient-Centered Outcomes Research Institute. Available from: https:\/\/www.pcori.org\/research-results\/about-our-research.  PCORI. About our research {Internet}. Washington (DC): Patient-Centered Outcomes Research Institute. Available from: https:\/\/www.pcori.org\/research-results\/about-our-research."},{"key":"e_1_3_2_1_17_1","unstructured":"PCORI. PCORI methodology standards {Internet}. Washington (DC): Patient-Centered Outcomes Research Institute. Available from: https:\/\/www.pcori.org\/research-results\/about-our-research\/research-methodology\/pcori-methodology-standards.  PCORI. PCORI methodology standards {Internet}. Washington (DC): Patient-Centered Outcomes Research Institute. Available from: https:\/\/www.pcori.org\/research-results\/about-our-research\/research-methodology\/pcori-methodology-standards."},{"key":"e_1_3_2_1_18_1","unstructured":"CTTI. Project: patient groups & clinical trials {Internet}. Durham (NC): Clinical Trials Transofrmation Initiative. Available from: https:\/\/www.ctti-clinicaltrials.org\/projects\/patient-groups-clinical-trials.  CTTI. Project: patient groups & clinical trials {Internet}. Durham (NC): Clinical Trials Transofrmation Initiative. Available from: https:\/\/www.ctti-clinicaltrials.org\/projects\/patient-groups-clinical-trials."},{"volume-title":"The future of clinical trials: industry voices {Internet}","author":"Burrows A.","key":"e_1_3_2_1_19_1","unstructured":"Burrows , A. The future of clinical trials: industry voices {Internet} . London : Knect 365. Available from:https:\/\/knect365.com\/clinical-trials-innovation\/article\/0e134709--42bc-4c70-a271-dead8fd43612\/industry-voices-future-clinical-trials-673533. Burrows, A. The future of clinical trials: industry voices {Internet}. London: Knect365. Available from:https:\/\/knect365.com\/clinical-trials-innovation\/article\/0e134709--42bc-4c70-a271-dead8fd43612\/industry-voices-future-clinical-trials-673533."},{"key":"e_1_3_2_1_20_1","unstructured":"FDA. Biomarker qualification program {Internet}. Silver Spring (MD): US Food and Drug Administration. Available from: https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/ DrugDevelopmentToolsQualificationProgram\/BiomarkerQualificationProgram\/default.htm.  FDA. Biomarker qualification program {Internet}. Silver Spring (MD): US Food and Drug Administration. Available from: https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/ DrugDevelopmentToolsQualificationProgram\/BiomarkerQualificationProgram\/default.htm."},{"key":"e_1_3_2_1_21_1","unstructured":"The precision medicine initiative {Internet}. Bethesda (MD): Precision Medicine Initiative. Available from: https:\/\/syndication.nih.gov\/multimedia\/pmi\/infographics\/pmi-infographic.pdf.  The precision medicine initiative {Internet}. Bethesda (MD): Precision Medicine Initiative. Available from: https:\/\/syndication.nih.gov\/multimedia\/pmi\/infographics\/pmi-infographic.pdf."},{"key":"e_1_3_2_1_22_1","unstructured":"Liu P. China initiative would pour billions into precision medicine {Internet}. Available from: http:\/\/www.bioworld.com\/content\/china-initiative-would-pour-billions-precision-medicine-0.  Liu P. China initiative would pour billions into precision medicine {Internet}. Available from: http:\/\/www.bioworld.com\/content\/china-initiative-would-pour-billions-precision-medicine-0."},{"key":"e_1_3_2_1_23_1","unstructured":"Cyranoski D. China embraces precision medicine on a massive scale {Internet}. Available from: https:\/\/www.nature.com\/news\/china-embraces-precision-medicine-on-a-massive-scale-1.19108.  Cyranoski D. China embraces precision medicine on a massive scale {Internet}. Available from: https:\/\/www.nature.com\/news\/china-embraces-precision-medicine-on-a-massive-scale-1.19108."},{"key":"e_1_3_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1609216"},{"key":"e_1_3_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5262"},{"key":"e_1_3_2_1_26_1","unstructured":"PMDA. \"Rational Medicine\" Initiative. Tokyo: Pharmaceuticals and Medicines Devices Agency 2017.Available from: https:\/\/www.pmda.go.jp\/files\/000216304.pdf.  PMDA. \"Rational Medicine\" Initiative. Tokyo: Pharmaceuticals and Medicines Devices Agency 2017.Available from: https:\/\/www.pmda.go.jp\/files\/000216304.pdf."},{"key":"e_1_3_2_1_27_1","unstructured":"FDA. Use of real-world evidence to support regulatory decision-making for medical devices. Silver Spring (MD): US Food and Drug Administration. Available from: https:\/\/www.fda.gov\/downloads\/medicaldevices\/deviceregulationandguidance\/guidancedocuments\/ucm513027.pdf.  FDA. Use of real-world evidence to support regulatory decision-making for medical devices. Silver Spring (MD): US Food and Drug Administration. Available from: https:\/\/www.fda.gov\/downloads\/medicaldevices\/deviceregulationandguidance\/guidancedocuments\/ucm513027.pdf."},{"key":"e_1_3_2_1_28_1","volume-title":"Real-world data and evidence in drug development. Silver Spring (MD): US Food and Drug Administration","author":"Chronicles","year":"2017","unstructured":"CDER SBIA Chronicles . Real-world data and evidence in drug development. Silver Spring (MD): US Food and Drug Administration , 2017 . Available from: https:\/\/www.fda.gov\/downloads\/drugs\/developmentapprovalprocess\/smallbusinessassistance\/ucm572939.pdf. CDER SBIA Chronicles. Real-world data and evidence in drug development. Silver Spring (MD): US Food and Drug Administration, 2017. Available from: https:\/\/www.fda.gov\/downloads\/drugs\/developmentapprovalprocess\/smallbusinessassistance\/ucm572939.pdf."},{"key":"e_1_3_2_1_29_1","volume-title":"eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","author":"Public","year":"2015","unstructured":"EMA. Public summary of opinion on orphan designation : eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria . London : European Medicines Agency , 2015 . Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2009\/10\/WC500006161.pdf. EMA. Public summary of opinion on orphan designation: eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. London: European Medicines Agency, 2015. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2009\/10\/WC500006161.pdf."},{"key":"e_1_3_2_1_30_1","volume-title":"Soliris case: PNH indication update based on data from the global registry","author":"Zimmermann M.","year":"2016","unstructured":"Zimmermann , M. Soliris case: PNH indication update based on data from the global registry . London : European Medicines Agency , 2016 . Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Presentation\/2016\/12\/WC500217727.pdf. Zimmermann, M. Soliris case: PNH indication update based on data from the global registry. London: European Medicines Agency, 2016. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Presentation\/2016\/12\/WC500217727.pdf."},{"key":"e_1_3_2_1_31_1","volume-title":"The Salford lung study","author":"Woodcock A.","year":"2016","unstructured":"Woodcock , A. and Leather , D . The Salford lung study . London : European Medicines Agency , 2016 . Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Presentation\/2016\/12\/WC500218600.pdf. Woodcock, A. and Leather, D. The Salford lung study. London: European Medicines Agency, 2016. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Presentation\/2016\/12\/WC500218600.pdf."},{"key":"e_1_3_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205259"},{"key":"e_1_3_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00157"},{"key":"e_1_3_2_1_34_1","doi-asserted-by":"crossref","unstructured":"Curran G. M. Bauer M. Mittman B. etal Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact.Med Care. 2012;50(3):217--26.  Curran G. M. Bauer M. Mittman B. et al. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact.Med Care. 2012;50(3):217--26.","DOI":"10.1097\/MLR.0b013e3182408812"},{"issue":"4","key":"e_1_3_2_1_35_1","first-page":"520","article-title":"Policies for Use of Real-World Data in Health technology assessment (HTA): A Comparative Study of Six HTA Agencies. The value","volume":"20","author":"Makady A.","unstructured":"Makady , A. , Ham , R. T. , de Boer , A. , Policies for Use of Real-World Data in Health technology assessment (HTA): A Comparative Study of Six HTA Agencies. The value in Health . 20 ( 4 ): 520 -- 532 . Makady, A., Ham, R. T., de Boer, A., et al. Policies for Use of Real-World Data in Health technology assessment (HTA): A Comparative Study of Six HTA Agencies. The value in Health.20(4):520--32.","journal-title":"Health"}],"event":{"name":"DMIP '18: 2018 International Conference on Digital Medicine and Image Processing","acronym":"DMIP '18","location":"Okinawa Japan"},"container-title":["Proceedings of the 2018 International Conference on Digital Medicine and Image Processing"],"original-title":[],"link":[{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3299852.3299854","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dl.acm.org\/doi\/pdf\/10.1145\/3299852.3299854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T01:39:15Z","timestamp":1750210755000},"score":1,"resource":{"primary":{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3299852.3299854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":35,"alternative-id":["10.1145\/3299852.3299854","10.1145\/3299852"],"URL":"https:\/\/doi.org\/10.1145\/3299852.3299854","relation":{},"subject":[],"published":{"date-parts":[[2018,11,12]]},"assertion":[{"value":"2018-11-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}